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Abstract: Women with autoimmune diseases such as lupus, scleroderma, and vasculitis receiving cyclophosphamide for severe disease 
manifestations risk primary ovarian insufficiency (POI) due to gonadotoxicity of this therapy. In addition to loss of reproductive poten-
tial, POI is associated with increased risk of morbidity and mortality. Practitioners caring for women requiring gonadotoxic therapies 
should be familiar with long-term health implications of POI and strategies for ovarian preservation. Accumulating evidence supports 
the effectiveness of adjunctive gonadotropin releasing hormone analog (GnRH-a) for ovarian protection during gonadotoxic therapy 
in cancer and autoimmune populations. GnRH-a is less costly and invasive than assisted reproductive technologies used for achieve-
ment of future pregnancies, but is not Food and Drug Administration approved for ovarian preservation. This review focuses on POI 
comorbidities and strategies for mitigation of related sequelae, which can accumulate over decades of hypoesteogenism. These issues 
are arguably more pronounced for women with chronic autoimmune diseases, in whom superimposed POI further heightens risks of car-
diovascular disease and osteoporosis. Therefore, even if future pregnancy is not desired, ovarian protection during gonadotoxic therapy 
should be a major goal of disease management.
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Introduction
Severe manifestations of autoimmune diseases, such 
as systemic lupus erythematosus (SLE), systemic 
sclerosis, and vasculitis, often require treatment 
with gonadotoxic immunosuppressive medications, 
particularly cyclophosphamide (CYC). While CYC 
administration prolongs survival in these diseases, 
it is associated with significant toxicity, including 
an unacceptably high incidence of primary ovarian 
insufficiency (POI) in female patients, with con-
sequent irreversible amenorrhea and infertility.1–3 
Beyond reproductive implications, POI is associated 
with broad and long lasting detrimental effects on 
general health, quality of life, and life expectancy.4–6 
With autoimmune diseases often affecting women 
during their reproductive years,7 it is imperative that 
the risks of prolonged hypoestrogenemia associated 
with gonadotoxic therapies are adequately recog-
nized when formulating treatment plans. These issues 
have been rigorously addressed in the field of oncol-
ogy, as is evidenced by the development of practice 
guidelines for fertility preservation in the cancer 
 population.8 In comparison, rheumatologists have 
yet to develop similar practice guidelines for fertility 
preservation in rheumatic disease patients undergo-
ing treatment with gonadotoxic chemotherapy.
In this broad overview, we aim to: (a) increase 
awareness and understanding of potential health con-
sequences, beyond infertility, of gonadotoxic therapies 
in young women; and (b) highlight potential strategies 
for mitigation of such risks and resulting comorbidi-
ties, including methods for ovarian protection.
Triple Threat of primary Ovarian 
Insufficiency, Underlying Autoimmune 
Disease, and Treatment Side Effects
Menopause before the age of 40 years is considered 
to be premature.5 The term “primary ovarian insuf-
ficiency,” rather than “primary ovarian failure” or 
 “premature menopause,” is the currently preferred 
term, as it is less stigmatizing and allows the condition 
to be viewed as a continuum of impaired ovarian func-
tion as opposed to a dichotomous state.9–11 POI has 
become recognized as “a serious and incurable chronic 
disease,” the diagnosis of which requires a woman to 
be less than 40 years old, have experienced amenor-
rhea for 4 months or more, and she has to have two 
serum follicle stimulating hormone levels obtained at 
least 1 month apart in the menopausal range.5 Unlike 
natural menopause, which occurs on average at age 
50 years,12 50% of women with POI still have varia-
tions in ovarian function, and 5%–10% conceive and 
deliver a child after receiving the diagnosis.5,13,14
While sequelae apply to all causes of POI (which is 
most frequently considered to be idiopathic, affecting 
1% of women under the age of 40 years),15,16 symptoms 
are compounded in women with autoimmune diseases. 
Both the underlying  autoimmune/inflammatory pro-
cesses and their treatments (eg, corticosteroids) are 
associated with many serious long-term consequences 
of hypoestrogenism, most notably cardiovascular dis-
ease and loss of bone mineral density.17–21 These poten-
tial long-term consequences of ovarian damage, beyond 
infertility, may be overlooked in women with autoim-
mune diseases requiring CYC (often on an urgent or 
semi-urgent basis), and particularly among patients 
who may not be concerned with future childbearing.
Medications used in Autoimmune 
Diseases Associated with pOI  
and common sequelae
Alkylating agents
Alkylating agents such as CYC and chlorambucil are 
immunosuppressive medications used to treat severe 
manifestations of autoimmune diseases, including 
SLE, systemic sclerosis, and vasculitis, and they are 
used as part of chemotherapeutic regimens for both 
hematologic malignancies and solid tumors. Even as 
potentially less toxic alternatives for CYC therapy 
become more widely applied (eg, mycophenolate 
mofetil),22,23 CYC is still indicated in patients with 
organ-threatening manifestations of severe autoim-
mune disease. In humans, CYC-induced ovarian 
damage is generally regarded as cumulative and irre-
versible, due in part to the progressive reduction of 
a limited number of primordial follicles.1–3 Among 
female patients treated with CYC for rheumatic dis-
ease or malignancy, POI develops in 12% to 83%, 
depending on variables including patient age, mode 
of administration, and cumulative CYC dose, all of 
which are strong predictors of POI.2,3,24–27 CYC may 
also contribute directly to bone loss, even beyond its 
potential to induce a hypoestrongenic state.28,29 In ani-
mal models, CYC decreases the number of osteoclasts 
and osteoblasts on bone surfaces, and exerts adverse 
effects on epiphyseal growth plates.30,31
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Glucocorticoids
Large cumulative doses of glucocorticoid therapy 
(GC), either by intravenous bolus dosing or through 
prolonged daily oral therapy, have been associated 
with side effects including accelerated atherosclero-
sis and osteoporosis.20,21,32–35 Although glucocorticoid 
therapy is a cornerstone of treatment for patients with 
autoimmune diseases, efforts are continually being 
made to decrease cumulative exposure by maintain-
ing patients on immunosuppressive “steroid-sparing” 
agents such as methotrexate, azathioprine, and myco-
phenolate mofetil. At high intravenous doses (eg, 
.250 mg), the most common immediate side effects 
of glucocorticoid therapy include elevation of dia-
stolic blood pressure, cardiac arrhythmia, hyperglyce-
mia, and flushing.36 Long-term, moderate daily doses 
of prednisone, defined as .7.5 mg to 30 mg a day 
for more than 2–3 months are associated with a range 
of adverse outcomes, including myopathy, glaucoma, 
cataracts, infections, avascular necrosis, weight gain, 
and various mood disturbances including depression, 
anxiety, and even psychosis.37–39 Even at low daily 
doses (less than 7.5 mg/day), side effects of gluco-
corticoids such as acne, easy bruising, weight gain, 
and cataracts are seen in patients who are treated for 
more than 90 days,40–43 although the actual frequency 
of adverse events at low doses is not as well charac-
terized as that associated with higher dose therapy.38 
Physicians caring for patients treated with gluco-
corticoids at any dose must be aware of these risks, 
many of which are compounded in patients with POI. 
In particular, patients with POI may be at risk for 
decreased bone density if they lose estrogen during 
their twenties and thirties, when spinal bone mineral 
density (BMD) increases significantly, peaking in the 
mid-thirties.44 (Rodin et al 1990) Exposure to medica-
tions that deplete BMD and induce a hypoestrogenic 
state prior to or during these years may prevent young 
women from reaching a normal BMD.
comorbidities Associated with pOI
All-cause mortality
All-cause mortality has been shown to increase two-
fold with early menopause.45 Large observational 
studies of women who experience idiopathic meno-
pause at an age of less than 50 years have revealed 
significantly increased age-adjusted risk of death 
compared to women experiencing natural menopause 
at an age greater than 50 years.4,46 Similarly, mortality 
has been shown to be significantly higher in women 
who undergo oophorectomy before age 45 versus 
referent women.47 Recently, prospective data from 
a large, homogenous population-based study evalu-
ating the risk of fracture and mortality associated 
with age at menopause revealed that at 34 years of 
follow-up, women undergoing menopause before age 
47 had increased risks of mortality, fragility fractures, 
and osteoporosis at age 77.48
Cardiovascular disease
POI of any cause may also be associated with increased 
morbidity and mortality from cardiovascular disease 
(CVD) due to premature loss of the protective effects 
of estrogen.45,46 Data from several large cohort studies 
confirm the presence of a heightened CVD risk among 
women who had a bilateral oophorectomy before age 
40 compared to after age 45, and the effect of exog-
enous estrogen was not necessarily protective.49,50 
The Mayo Clinic Cohort Study of Oophorectomy and 
Aging, which included over 2,000 cases of unilateral 
or bilateral oophorectomy compared to over 2,300 
referent women who did not undergo oophorectomy, 
found increased mortality from CVD associated with 
bilateral oophorectomy if patients were not treated 
with HT until or past the age of 45 (HR 1.84, 95% 
CI 1.27–2.68).51 Large scale epidemiologic studies of 
women with POI demonstrate CVD occurring at higher 
rates and at younger ages in women with POI than in 
control women, although not all results reached statis-
tical significance.45,52–57 For example, Snowden et al4 
found an increased risk of death, though this did not 
reach statistical significance, from coronary heart dis-
ease (adjusted OR 1.59, 95% CI 0.58–4.40) and stroke 
(adjusted OR 1.87, 95% CI 0.51–6.92) in women expe-
riencing natural menopause at an age younger than 40 
years as compared to those experiencing menopause 
at older than 50 years.
Bone density
Osteoporosis is associated with hypoestrogenism due 
to ovarian insufficiency or natural menopause.58 Both 
the time since the onset of menopause and increased 
chronological age are associated with lower bone 
density,59 underscoring the well-recognized risk to 
bone health that accumulates over decades after early 
menopause.58,60,61 In a population-based prospective 
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study of Swedish women that were followed from the 
age of 48 years onwards, the authors reported that by 
age 77, a significantly higher proportion of women 
who had undergone early menopause had osteopo-
rosis (BMD by dual energy X-ray absorptiometry of 
hip and lumbar spine) compared to women with late 
or natural menopause (56% versus 30%, respectively, 
P = 0.01).48 Other cross sectional studies support the 
findings of significantly lower BMD in women under-
going oophorectomy prior to menopause as com-
pared to women undergoing natural menopause.62,63 
Osteoporotic fracture rates before the age of 70 are 
also significantly higher among women with early 
menopause.64–67 This problem is compounded in 
women with autoimmune diseases who experience 
early menopause, as they have underlying risks for 
osteoporosis not only due to chronic steroid use, but 
due to proinflammatory cytokines that drive their 
underlying inflammatory disease.33,68–71 Furthermore, 
women with SLE have further increased risk factors 
for low bone density, as they often have low vita-
min D levels, which are associated with sun avoid-
ance (related to photosensitivity) and with periods of 
active lupus disease activity.72–74
Mental health and neurocognition
The distress associated with POI differs from that 
experienced by women with natural menopause, 
which may be due, in part, to the abrupt and unex-
pected nature of the diagnosis.75–77 In a study of 
100 women with idiopathic POI, 84% of women felt 
both unprepared emotionally for their diagnosis, and 
that the diagnosis had created moderate to severe 
suffering in their lives.75 Beyond the initial stress of 
the POI diagnosis, many studies have documented 
increased rates of anxiety, depression, somatization, 
negative affect, hostility, or sensitivity among women 
with POI.76,78–80 A number of studies have also exam-
ined the effects of POI on a woman’s sense of self, 
and have found a significant association with POI and 
lowered self-esteem, as well as with a feeling of loss 
of femininity.76,81–84
Neurocognitive deficits in women with POI have 
also been reported, including higher rates of cogni-
tive impairment, dementia, and Parkinson’s disease 
in women with oophorectomy when compared with 
controls.85–87 Some of these conditions may have 
a cumulative effect in women with autoimmune 
 diseases such as SLE, for example, in whom preex-
isting rates of depression and cognitive dysfunction 
are increased compared with healthy controls.88,89 
These associations were stronger for those undergo-
ing oophorectomy at a younger age, supporting the 
hypothesis that estrogen may have a protective effect 
against the neurodegenerative processes associated 
with natural aging.
Quality of Life
vasomotor and sexual dysfunction
Classic symptoms of natural menopause such as hot 
flashes and night sweats are also prevalent among 
women with POI, and can be more severe in women 
who experience menopause at a younger age.87 In a 
report by Mar Fan,90 51.4% of 41 women with che-
motherapy-induced POI experienced moderate to 
severe hot flashes, as compared with only 19.3% of 
57 women undergoing natural menopause, at 1-year 
follow-up. Besides the immediate discomfort, these 
episodes of vasomotor instability can disturb sleep 
and interrupt daily life, leading to impaired mood 
and frustration.91 These symptoms represent the most 
common reason that women request treatment with 
HRT, which effectively relieves hot flashes for a 
majority of patients.
Studies have consistently shown that women 
with POI experience greater rates of sexual dys-
function than control women of comparable ages. 
Vaginal dryness and associated dyspareunia are com-
monly reported symptoms of sexual dysfunction 
among women with idiopathic POI, oophorectomy, 
 chemotherapy-induced POI, and diminished ovarian 
reserve.16,78,92–95 These symptoms can lead to a vari-
ety of related problems such as difficulty with sexual 
arousal, satisfaction, and difficulty reaching orgasm, 
often translating into emotional distress and impaired 
intimacy, or avoidance of sexual contact.16,75
Interpersonal relationships
Sexual dysfunction can affect the experience of a 
woman’s partner as well, and some data suggests that 
it could lead to sexual impairment in males.81 In cases 
where a woman’s partner may be desiring children, 
the loss of fertility may also place an added burden 
on the relationship.97 The experience of menopause 
at a young age has also been described as creating a 
disconnect between a young woman and her peers, 
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making her feel older and less able to relate to mates 
of similar ages.91
When POI occurs in the context of chronic illness, 
it is difficult to assess the impact of ovarian function 
alone on quality of life. The studies assessed in this 
review represent a variety of populations and con-
trol groups, yet the consistency of results across the 
studies of POI suggests that it significantly impacts 
quality of life regardless of underlying health and 
prognosis. Short versus long-term effects of POI may 
also confound quality of life assessments.  Symptoms 
in idiopathic POI that impact quality of life may begin 
months before amenorrhea or the actual diagnosis of 
menopause, making it difficult to accurately assess 
women’s perceptions of the effects of POI. Some 
quality of life outcomes may also capture short-
term consequences that may not last more than a 
few months after the onset of  menopause.  Therefore, 
the overall impact of POI on the perception of qual-
ity of life may be confounded by the duration of 
symptoms.
Mitigation of Ovarian Damage after 
cyclophosphamide
Alternatives to use of bolus CYC
In an effort to reduce exposure to CYC, several newer 
therapeutic options have been investigated for the 
treatment of severe manifestations of autoimmune 
diseases. The use of CYC as induction therapy for 
lupus nephritis (LN) is declining since the introduc-
tion of induction therapy with mycophenolate mofetil 
(MMF), which may be an adequate initial therapy for 
mild LN, is well-tolerated,23,97 and is not associated 
with gonadotoxicity. A subset of LN patients may 
also respond to the “Euro-lupus” regimen, consisting 
of six doses of 500 mg CYC given every 2 weeks, 
followed by azathioprine.98 The resulting total CYC 
exposure of 3 grams is much lower than cumulative 
doses given in standard 6-month courses for LN. 
However, patients with severe proliferative LN with 
renal insufficiency, and those who do not respond 
initially to MMF, will still require standard monthly 
intravenous CYC therapy. Similarly, use of the anti-
CD20 monoclonal antibody, rituximab, may be an 
effective alternative to CYC in some patients with 
systemic vasculitis,99 further expanding treatment 
options beyond cyclophosphamide for patients with 
autoimmune diseases.
Ovarian protection
A number of assisted reproductive technolo-
gies exist (eg, oocyte, embryo, or ovarian tissue 
cryopreservation), which may increase the chances of 
future childbearing for women undergoing gonado-
toxic therapy; however, these “high-tech” reproduc-
tive strategies do not address the preservation of 
ovarian function and its attendant health benefits, 
which can be extremely costly, and usually requires a 
delay in medical treatment.
Adjunctive oral contraceptive use during gonad-
otoxic therapy has been proposed for the preserva-
tion of ovarian function, but convincing evidence 
regarding its efficacy for this purpose is lacking.100 
However, the accumulating data from our group and 
others suggest that adjunctive treatment with gonado-
tropin releasing hormone analog (GnRH-a) during 
CYC therapy protects against the loss of the ovarian 
reserve, as measured by gradations in  anti-Mullerian 
hormone, a biomarker of the ovarian reserve.101 
 Currently, we are conducting an National Institutes of 
Health-sponsored multicenter randomized controlled 
trial of GnRH-a for ovarian protection in women 
with autoimmune diseases receiving CYC, in order to 
more definitively assess the efficacy of the GnRH-a 
regimen in this patient population. GnRH-a therapy is 
far less costly and invasive than other potential meth-
ods for fertility preservation. If confirmed as effica-
cious, the health benefits beyond fertility preservation 
would make this an important adjunctive therapy to 
consider regardless of childbearing intentions. If the 
efficacy of GnRH-a is not confirmed in randomized 
controlled trials, future interventions should be devel-
oped with the preservation of ovarian function as a 
primary therapeutic strategy.
Management of pOI in Women  
with Rheumatic Diseases
In 2012, the North American Menopause Society 
addressed the issue of hormone therapy (HT) for 
women with POI in a position statement on the use 
of HT in post-menopausal women.102 The authors 
advised that in general, women who experience pre-
mature menopause—because of their increased risk of 
osteoporosis, possible increased CVD risk, and their 
more intense hypoestrogenemic symptoms—should 
take HT until at least the median age of menopause. 
While the authors acknowledged that no comparative 
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data exist, they state that potential benefits for women 
with POI may outweigh the risks associated with tak-
ing HT. Furthermore, the risks associated with POI 
may actually be fewer than those incurred by older 
women who commence HT at or beyond the median 
age of menopause; specifically, the heightened risks 
of cardiovascular events and breast cancer have been 
observed among post-menopausal women treated with 
HT as part of the Women’s Health Initiative.103 Results 
from the Women’s Health Initiative, however, do not 
necessarily apply to the population of women with 
POI, who would receive HT as a replacement until the 
age of natural menopause, and not as supplementary 
therapy past the age when the body stops naturally 
producing gonadal hormones. However, HT is con-
traindicated in patients with increased thrombotic risk, 
including women with antiphospholipid antibodies 
either as a primary syndrome, or secondary to auto-
immune diseases such as SLE. Hypercoagulability 
has also been documented in patients with granulo-
matosis with polyangiitis (formerly Wegener’s).104 
Therefore, the best strategy to try to prevent the loss 
of naturally occurring gonadal hormones, as the best 
levels recommended for replacement and even the 
method of delivery of HT for patients with POI have 
not been well established.
Although few, the currently existing randomized 
controlled trials that address HT recommendations 
for women with POI have compared physiological 
sex steroid replacement versus standard HT (oral 
ethinylestradiol and norethisterone), and found that 
those women treated with the physiologic replace-
ment had improved markers of CVD, including 
lower blood pressure, improved renal function, and 
less activation of the renin-angiotensin system, as 
well as improvement in markers of bone mineral 
density in the lumbar spine.105,106 However, these 
studies focused on proxies of disease, and it remains 
unclear if this treatment simply replaces estrogen 
until the presumed natural menopause affords young 
women the same health benefits as the experience 
of premenopausal women. Even if personalized HT 
treatment strategies with favorable risk-benefit pro-
files are developed for women with POI, poor com-
pliance with decades of HT is frequently observed. 
In one study, only 48% of women with POI were 
taking HT, with 85% citing increased risk of cancer, 
stroke, and heart attack as concerns regarding long-
term HT.107
conclusions
It has been our experience that long-term health 
consequences beyond the preservation of fertility 
(eg, the ability to conceive a child either in vitro or 
in vivo), including issues of psychosocial and sex-
ual health related to POI are often overlooked in the 
rheumatic disease patient population. This may be 
due to the sense of urgency in treating the severe 
active disease, or to lack of awareness on the part 
of the practitioner. When faced with the decision to 
use CYC in premenopausal patients, the burden of 
disease resulting from POI beyond the loss of fertil-
ity must be considered, as it confers on our patients 
another chronic condition that must be managed in 
the context of their underlying autoimmune disease. 
With survival rates among patients with autoim-
mune diseases and many malignancies improving 
over time,108,109 attention to long-term health and 
quality of life for patients facing gonadotoxic ther-
apy during their reproductive years must be incorpo-
rated into their health care plan as early as possible. 
A broad focus on ovarian protection and related 
women’s health issues, rather than a focus on fertil-
ity preservation as the singular goal, is the paradigm 
shift we have tried to emphasize in this review by 
describing the wide variety of deleterious outcomes 
beyond the loss of fertility that are associated with 
POI due to any cause.
Options for fertility preservation that also pre-
vent POI (for example, the use of GnRH-a during 
CYC therapy) are increasingly advocated for use 
in rheumatic and some oncologic diseases.101,110–117 
Promising results in women with SLE treated with 
GnRH-a during CYC make this therapy attractive, 
and give GnRH-a a clear advantage over vastly 
more expensive, invasive, and inconvenient thera-
pies such as cryopreservation of embryos or ovarian 
tissue. The extensive comorbidities associated with 
POI discussed in this article, compounded by poor 
compliance with HT, as well as contraindications 
for HT among patients with hypercoagulability, 
make prevention of POI the most attractive strategy. 
If ovarian protection can be achieved with simple, 
adjunctive GnRH-a therapy, prevention of POI-
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related comorbidities over time would be clearly 
cost-effective, which is in  contrast to assisted repro-
ductive technologies, which are costly, labor inten-
sive, and focus solely on fertility without addressing 
gonadal protection and long-term health issues asso-
ciated with hypoestrogenism. We and others feel 
that GnRH-a has the best likelihood (among cur-
rently available options) of preventing POI in our 
patient population receiving CYC, and we have pub-
lished our protocol detailing timing and dosing dur-
ing CYC therapy.116 However, in advance of results 
from ongoing clinical trials, such use of GnRH-a is 
considered “off label.” Clearly, increased awareness 
of the health risks associated with POI is needed. 
Research efforts should continue to focus on pre-
vention and mitigation of the chronic and complex 
sequelae of POI in this patient population.
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